Showing 1-10 of about 45 articles.
Emergent BioSolutions
GAITHERSBURG, Md., April 16, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and...
Vystar Corp
Destroys on first pass more than 99.97% of harmful airborne viruses and bacteria.Inactivates pathogens that cause measles, the common cold, MRSA (staph), whooping cough, TB, pneumonia and other...
Vystar Corp
Features longer-lasting, more effective UV light for more efficient inactivation of viruses and bacteriaRxAir available for medical, business and residentialRxAir now available via Vystar’s medical...
Natural Immunogenics Corp.
SARASOTA, Fla., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Stephen L. Quinto may not have been born with a silver spoon in his mouth, but his breakthrough discovery has advanced colloidal silver technology...
Vystar Corp
UV Flu Technologies Air Purifiers Destroy Viruses and BacteriaPurchase creates additional Vystar revenue stream WORCESTER, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Vystar Corporation (OTCPink:VYST)...
Kanguru Solutions
Millis, MA USA, April 30, 2018 (GLOBE NEWSWIRE) -- Data-greedy villains are constantly lurking in the shadows, ready to take advantage of their next victim. They prey on every opportunity they...
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - December 06, 2016) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of the...
Hemispherx Biopharma, Inc.
PHILADELPHIA, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that it is beginning to consider study designs for potential tests of the activity and...
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A.,...
Hemispherx Biopharma, Inc.
PHILADELPHIA, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the results of a new efficacy study of Ampligen® in a...
Showing 1-10 of about 45 articles.
